Opinion

Video

When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Eric Winer, MD
2 expert is featured in this series.